Logo Image
Feature|Videos|August 7, 2026

Onshoring Commitments and the Public Narrative Behind Them

Key Takeaways

  • Understand why companies committing to new onshoring investments should expect FDA inspection findings rather than assume a smooth approval process.
  • Learn why cross-functional coordination across government affairs, regulatory, legal, and quality teams is essential to a successful onshoring investment.
SHOW MORE

Rachel Turow and Maggie Farley examine what's really at stake as companies commit to new U.S. manufacturing — from FDA inspection risk to how these announcements are covered in the press.

Episodes in this series

In this segment, Rachel Turow of Skadden and Maggie Farley of RC Resolve examine the operational and reputational stakes of new U.S. manufacturing commitments.

Turow explains that FDA inspection deficiencies are common, even in well-built facilities, and that companies making onshoring commitments should treat them as long-term investments rather than expect an immediate path to market — noting that a coordinated effort across government affairs, regulatory, legal, quality, and facilities teams is essential from the outset. Farley then discusses how manufacturing and reshoring announcements become public narratives, cautioning that the same news can be read as a reputational win by one audience and a reputational drag by another, and that companies need narratives ready to withstand that kind of reinterpretation as it spreads across the stakeholder universe.

Regulatory affairs, quality, and communications leaders will gain practical guidance on preparing for both the regulatory and reputational realities of a major onshoring investment.